United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock on September 16, 2026 at an exercise price of $117.76 per share, receiving 9,500 shares indirectly.
On the same date, the family trust sold 9,500 shares of common stock in multiple transactions at prices ranging from $497.69 to $505.26 per share. These trades were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which will continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026. After the option exercise, a family trust associated with the reporting person held 423,410 stock options with the same March 15, 2027 expiration.
UNITED THERAPEUTICS CORPORATION (UTHR) has an officer, Paul Mahon, filing a notice of proposed sale of restricted or control common stock under Rule 144. The notice covers 8,300 shares of common stock, with an aggregate market value of $4,129,607.73, relative to 42,890,692 shares outstanding as of September 17, 2026.
The filing notes the shares are tied to a stock option exercise for cash on September 17, 2026, with Morgan Stanley Smith Barney LLC listed as the broker. Mahon also reports a pattern of prior Rule 144 sales, each for 8,300 shares, on six dates between June 18, 2026 and September 3, 2026, with reported aggregate prices ranging from about $4.00 million to $4.59 million per sale.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options on September 15, 2026 at an exercise price of $117.76 per share and acquired an equal number of common shares. The trusts then sold 9,500 common shares in multiple open-market transactions at weighted average prices around $500–$505 per share, all pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following the option exercise, family trusts report holding 432,910 stock options from the same grant, while Rothblatt also reports 40,513 UTHR shares held directly and 166 shares held indirectly by spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options at an exercise price of $117.76 per share on September 14, 2026, receiving 9,500 common shares and then selling those 9,500 shares in multiple open-market trades around $502–$506 per share. The option exercise and related sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and 442,410 options of this grant remain held by a family trust after the exercise.
UNITED THERAPEUTICS Corp (UTHR) director Nilda Mesa exercised stock options for 130 shares of common stock on September 14, 2026 at an exercise price of $110.86 per share, then sold a total of 228 shares in two transactions at prices around $505.8 per share. Following the option exercise, she held 6,430 stock options directly, and no transactions were reported under a Rule 10b5-1 trading plan.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at $117.76 per share and on September 11, 2026 sold 9,500 common shares in multiple trades at prices around $497–$508 per share. After the exercise, the trust held 451,910 stock options, while separate holding entries show 40,513 shares held directly and 166 shares held indirectly by spouse. The option exercise and related sales were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 options expiring March 15, 2027 or December 31, 2026.
UNITED THERAPEUTICS CORPORATION (UTHR) is the issuer for a planned sale of its common stock reported by director Nilda Mesa under Rule 144. The notice covers 228 shares of common stock to be sold through Morgan Stanley Smith Barney LLC on NASDAQ on September 14, 2026, with an aggregate market value of $115,337.83.
UNITED THERAPEUTICS Corp (UTHR) Chairperson & CEO Martine A. Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 10, 2026, and sold the resulting 9,500 common shares in multiple trades around $498–$509 per share.
The option exercise and related sales were made under a Rule 10b5-1 trading plan adopted on November 7, 2025. After the exercise, a family trust held 461,410 stock options expiring March 15, 2027, and Rothblatt also reported 40,513 common shares held directly and 166 shares held indirectly by spouse.
UNITED THERAPEUTICS Corp (UTHR) reported that Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 9, 2026, and the resulting 9,500 shares were sold in multiple open-market transactions at prices generally around $494–$509 per share.
The option exercise was from a grant expiring March 15, 2027, leaving 470,910 options held indirectly by a trust after the transaction. The trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Rothblatt also reports 40,513 shares held directly and 166 shares held indirectly by a spouse, in addition to other trust holdings.
UNITED THERAPEUTICS Corp (UTHR) reports that Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options for common stock at an exercise price of $117.76 per share on September 8, 2026, and the trust sold 9,500 common shares in multiple trades on the same date.
The filing states these transactions were made pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, and that 480,410 stock options expiring March 15, 2027 remain held indirectly by a family trust after this exercise.